[Economic assessment of the routine use of Oncotype DX(R) assay for early breast cancer in Franche-Comte region].
Fiche publication
Date publication
juillet 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr NERICH Virginie, Pr PIVOT Xavier, Dr CURTIT Elsa
Tous les auteurs :
Nerich V, Curtit E, Bazan F, Montcuquet P, Villanueva C, Chaigneau L, Cals L, Meneveau N, Dobi E, Altmotlak H, Algros MP, Choulot MJ, Nallet G, Limat S, Mansion S, Pivot X
Lien Pubmed
Résumé
Oncotype DX(R) has been validated as quantifying the likelihood of distant recurrence at 10 years and overall chemotherapy benefit in patients with estrogen-receptor-positive and HER-2-negative early breast cancer. In 2012, this genomic signature was routinely available for patients in Franche-Comte, France. Patients eligible for Oncotype DX((R)) testing had a ER-positive, HER-2-negative early breast cancer with a nodal involvement limited to 0 or 1 positive-node without extracapsular spread; an adjuvant chemotherapy was indicated based on usual prognostic factors. The aim was to assess the economic impact of Oncotype DX((R)) testing in a French region. A cost-minimisation analysis from the French Public Healthcare System perspective was performed. The availability of Oncotype DX((R)) in Franche-Comte, France, and its use in clinical routine allowed a decrease of 73 % of adjuvant chemotherapy without increase of the cost of the patients' management and with a potential reduction of the cost for the French Public Healthcare System. This strategy was successful and may allow the reimbursement of this test in France for patients with early breast cancer.
Référence
Bull Cancer. 2014 Jul-Aug;101(7-8):681-9